(Q74841477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

author name string

R Angus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

E Quebe-Fehling

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

R Brambilla

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

publication date

1 March 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

562-567

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

Clinical pharmacology of long-acting beta-receptor agonists

13 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Rapid onset of action of inhaled formoterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Dry powder inhalers: advantages and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Influence of age on response to ipratropium and salbutamol in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Functional antagonism: tolerance produced by inhaled beta 2 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990309-2

7 January 2021

10.1016/S0954-6111(98)90309-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692123%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference